PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34377028-3	2021	Methods: We retrospectively analyzed the clinical effects of anlotinib + CRT versus CRT alone in NSCLC patients with BM and non-EGFR/ALK/ROS1-TKIs indication from September 2016 to June 2020.	anlotinib	61-70	ALK receptor tyrosine kinase	Homo sapiens	133-136	
33601493-0	2021	[Treatment of ALK negative metastatic inflammatory myofibroblastic tumor by combination of pembrolizumab and anlotinib: a case report].	anlotinib	109-118	ALK receptor tyrosine kinase	Homo sapiens	14-17